Literature DB >> 20981165

Screening for prostate cancer: a controversy or fact.

S Stavridis, S Saidi, Lj Lekovski, S Dohcev, G Spasovski.   

Abstract

BACKGROUND: Adenocarcinoma of the prostate is the most frequent malignancy in men and the second leading cause of death in the male population worldwide. The screening for prostate cancer allows early diagnosis of prostate malignancy before the individual presents with symptoms. The early stage of the disease is easier to manage by different therapeutic modalities. AIM: The aim of this review is to evaluate the reasons and facts for enthusiasm and positive approach towards the clinical decision about whether to screen or not male patients for early detection of prostate cancer.
METHODS: We performed a computerized MEDLINE search followed by a manual bibliographic review of cross-references. These reports were analyzed and the important findings were summarized. We analyzed the methods and schedule of screening, as well as advantages and disadvantages of the prostate cancer screening.
RESULTS: There were more than a hundred studies on prostate cancer screening performed but only a few are eligible for a decisive conclusion concerning the prostate cancer screening issue. We reviewed the screening methods, the schedule of screening, the advantages and disadvantages of prostate cancer screening.
CONCLUSION: The role for prostate cancer screening is not established yet. Definite proof of screening should be assumed as a decrease in the death rate of that cancer due to screening activity.

Entities:  

Keywords:  advantages; disadvantages; prostate carcinoma; review; role; schedule; screening

Year:  2010        PMID: 20981165      PMCID: PMC2943354     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  62 in total

1.  Leveling of prostate cancer mortality in Western Europe.

Authors:  Fabio Levi; Franca Lucchini; Eva Negri; Peter Boyle; Carlo La Vecchia
Journal:  Prostate       Date:  2004-06-15       Impact factor: 4.104

2.  Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.

Authors:  Renske Postma; Fritz H Schröder; Geert J L H van Leenders; Robert F Hoedemaeker; Andre N Vis; Monique J Roobol; Theodorus H van der Kwast
Journal:  Eur Urol       Date:  2007-01-16       Impact factor: 20.096

3.  Tumour features in the control and screening arm of a randomized trial of prostate cancer.

Authors:  Renske Postma; Arno G J L H van Leenders; Monique J Roobol; Fritz H Schröder; Theodorus H van der Kwast
Journal:  Eur Urol       Date:  2005-12-19       Impact factor: 20.096

Review 4.  Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening.

Authors:  Robert A Smith; Vilma Cokkinides; Otis W Brawley
Journal:  CA Cancer J Clin       Date:  2009 Jan-Feb       Impact factor: 508.702

Review 5.  Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.

Authors:  J C Presti; R Hovey; P R Carroll; K Shinohara
Journal:  J Urol       Date:  1996-11       Impact factor: 7.450

6.  Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.

Authors:  Mohamed H Radwan; Yan Yan; Jason R Luly; Robert S Figenshau; Steven B Brandes; Sam B Bhayani; Arnold D Bullock; Ye Liefu; Gerald L Andriole; Adam S Kibel
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

7.  Does prostate specific antigen density correlates with aggressiveness of the prostate cancer?

Authors:  S Saidi; V Georgiev; S Stavridis; D Petrovski; S Dohcev; L Lekovski; Z Popov; S Banev; G Spasovski
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

Review 8.  Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.

Authors:  Sanoj Punnen; Robert K Nam
Journal:  Surg Oncol       Date:  2009-03-12       Impact factor: 3.279

9.  Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden.

Authors:  Gabriel Sandblom; Eberhard Varenhorst; Owe Löfman; Johan Rosell; Per Carlsson
Journal:  Eur Urol       Date:  2004-12       Impact factor: 20.096

10.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

Authors:  M Ohori; T M Wheeler; J K Dunn; T A Stamey; P T Scardino
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  3 in total

1.  Utilization of prostate cancer screening according to dietary patterns and other demographic variables. The adventist health study-2.

Authors:  Yermek Ibrayev; Keiji Oda; Gary E Fraser; Synnove F Knutsen
Journal:  J Cancer       Date:  2013-06-28       Impact factor: 4.207

2.  Prostate cancer outcome in Burkina Faso.

Authors:  Fasnéwindé A Kabore; Barnabé Zango; Adama Sanou; Clotaire Yameogo; Brahima Kirakoya
Journal:  Infect Agent Cancer       Date:  2011-09-23       Impact factor: 2.965

3.  Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patients.

Authors:  Ali Sadeghi-Naini; Ervis Sofroni; Naum Papanicolau; Omar Falou; Linda Sugar; Gerard Morton; Martin J Yaffe; Robert Nam; Alireza Sadeghian; Michael C Kolios; Hans T Chung; Gregory J Czarnota
Journal:  Transl Oncol       Date:  2015-02       Impact factor: 4.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.